

Abstract

A subject of the present invention is to find utility of a combination of a Rho kinase inhibitor having a novel action and a β -blocker as a therapeutic agent for glaucoma. Actions of reducing intraocular pressure are complemented and/or enhanced each other by combining the Rho kinase inhibitor with the β -blocker. For the administration mode, each drug can be administered in combination or in mixture.